

anti-inflammatoxy and immuno-therapy - all results

Treatment	Number of studies	clinical deterioration	clinical improvement	deaths	viral clearance
Immunosuppressants drugs	38 studies ¹	0.48 [0.20 ; 1.20], 2 RCTs, I2=6% inconclusive result	1.44 [1.17 ; 1.78], 8 RCTs, I2=27% demonstrated moderate degree of certainty	0.81 [0.63 ; 1.04], 20 RCTs, I2=44% safety concern inconclusive result	-
Immunostimulants drugs	27 studies ²	0.63 [0.29 ; 1.40], 1 RCT, I2=0% inconclusive result	1.15 [0.96 ; 1.39], 10 RCTs, I2=48% inconclusive result	0.74 [0.56 ; 0.98], 22 RCTs, I2=41% moderate degree of certainty	6.97 [0.23 ; 210.35], 2 RCTs, I2=89% inconclusive result
corticosteroids	16 studies ³	0.66 [0.43 ; 1.02], 1 RCT, I2=0% inconclusive result	1.81 [0.89 ; 3.70], 3 RCTs, I2=72% inconclusive result	0.81 [0.57 ; 1.16], 10 RCTs, I2=67% inconclusive result	-
anti-inflammatory therapies	4 studies ⁴	0.27 [0.01 ; 5.58], 1 RCT, I2=0% inconclusive result	10.27 [1.17 ; 90.18], 1 RCT, I2=0% certainty unassessable	0.62 [0.21 ; 1.90], 3 RCTs, I2=0% inconclusive result	-

Notes

¹COV-BARRIER (critically ill), 2022 (NCT04421027); Amra, 2021 (IRCT20170207032444N3); Fakharian, 2021 (IRCT20151227025726N2); Hamed, 2021 (); Kumar, 2021 (CTRI/2020/05/024959); Les-cure (Sarilumab 200mg), 2021 (NCT04327388); Les-cure (Sarilumab 400mg), 2021 (NCT04327388); MARIPOSA, 2021 (NCT04363736); Rashad, 2021 (NCT04519385); REMAP-CAP (tocilizumab), 2021 (NCT02735707); REMAP-CAP sarilumab, 2021 (NCT02735707); Rosas (REMDACTA), 2021 (NCT04409262); Singh (TD-0903 10mg), 2021 (NCT04402866); Singh (TD-0903 1mg), 2021 (NCT04402866); Singh (TD-0903 3mg), 2021 (NCT04402866); Talaschian, 2021 (IRCT20081027001411N4); Veiga, 2021 (NCT04403685); ACTIV-1 abatacept, 2020 (NCT04593940); ACTIV-1 cenicriviroc, 2020 (NCT04593940); CAN-COVID, 2020 (NCT04362813); Cao, 2020 (); CORIMUNO-TOCI-1 (Group 1), 2020 (NCT04331808); CORIMUNO-TOCI-1 (Group 2), 2020 (NCT04331808); COVACTA (Rosas), 2020 (NCT04320615); ACTIV-1 infliximab, 0 (NCT04593940); DEVENT, 0 (NCT04377620); NCT04377750 (HMO-0224-20), 0 (NCT04377750); sarilumab Sanofi phase 3 outside US, 0 (); sarilumab Sanofi phase 3 US, 0 (NCT04315298); Tziolos, 2021 (); Andrew, 2020 (); ARI-RAF (Della-Torre), 2020 (); Biran, 2020 (); Mathilde, 2020 (); Rojas-Martel, 2020 (); Rossotti, 2020 (); Somers, 2020 (); TOCI-RAF Study Group (Campochiaro), 2020 ()

²CAPSID, 2021 (NCT04433910); CP-COVID-19, 2021 (NCT04332835); Darazam (COVIFERON Interferon beta-1a), 2021 (NCT04343768); Darazam (COVIFERON Interferon beta-1b), 2021 (NCT04343768); Kalil (ACTT-3), 2021 (NCT04492475); Lopardo, 2021 (NCT04494984); O'Donnell, 2021 (NCT04359810); Pouladzadeh, 2021 (IRCT20200310046736N1); Raman, 2021 (CTRI/2020/06/026222); RECOVER, 2021 (EudCT 2020-001632-10); REMAP-CAP (plasma), 2021 (NCT02735707); Sekine (PLACOVID), 2021 (NCT04547660); AlQahtani, 2020 (NCT04356534); Davoudi-Monfared, 2020 (IRCT20100228003449N2); Gharebaghi, 2020 (IRCT20200501047259N1); ILBS-COVID-02 (Bajpai M), 2020 (NCT04346446); Li, 2020 (ChiCTR2000029757); PICP19 (Ray), 2020 (CTRI/2020/05/025209); PlasmAr, 2020 (NCT04344535); Rahmani, 2020 (IRCT20100228003449N2); Rasheed, 2020 (); Tabarsi, 2020 (IRCT20151227025726N2); Duan, 2020 (); Hegerova, 2020 (); Sean, 2020 (); Bihariesingh-Sanchit (SuriCovid), 2021 (ISRCTN18304314); Joyner, 2020 (NCT04338360)

³COVID STEROID 2, 2021 (NCT04509973); Jamaati, 2021 (IRCT20151227025726N1); Munch (COVID-STEROID), 2021 (NCT04348305); Rashad, 2021 (NCT04519385); CAPE-COVID, 2020 (NCT02517489); CODEX (Tomazini), 2020 (NCT04327401); DEXA-COVID19, 2020 (NCT04325061); Edalatifard, 2020 (IRCT20200404046947N1); Farahani, 2020 (IRCT20200406046963N1); REMAP-CAP, fixed 7-day course, 2020 (NCT02735707); REMAP-CAP, shock-dependent course, 2020 (NCT02735707); Steroids-SARI, 2020 (NCT04244591); Jianfeng, 2020 (); Raef, 2020 (); Tomasz, 2020 (); Lu, 2020 ()

⁴COLCHIVID, 2021 (NCT04367168); Shi, 2020 (NCT04288102); Shu, 2020 (ChiCTR2000031494); Brunetti, 2020 ()